Salient facts

- Four articles produced by the team have gained particular interest:

  Dubois A et al. Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum. *Am J Respir Crit Care Med.* 2013 188:703-9. This article was discussed in 2 separate editorials (one appearing in 2013, and the other in 2014) in this same leading journal.


  Henry et al. In vitro and in vivo evidence for an inflammatory role of the calcium channel TRPV4 in lung epithelium: Potential involvement in cystic fibrosis. *Am J Physiol Lung Cell Mol Physiol.* 2016 311:L664-75. This article was distinguished by this journal in its APSselect section/“APSselect is a collection of the very best original research papers published by the American Physiological Society” (http://apsselect.physiology.org)

- Acquisition of 3 European patents:

  EP N°14306943.3 filed in December 2014 “METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE”
Organisation of 3 international conferences in Tours:


Joint organisation of 2 international conferences abroad (as part of the function of Chair of the GREMI association) held by M. Si-Tahar since March 2015:


IAIS meeting: Regulatory checkpoints and resolution, Florence, Italy (2016). Jointly organised with Labex Inflamex, SIF and GREMI.

Acquisition in late 2015 of a European funding for the “Joint Programming Initiative on Antimicrobial Resistance” (theme: Repurposing disused antibiotics with immune modulators as antimicrobial strategy for respiratory tract infections; coordinator: Dr. JC Sirard, CIIL, Lille).

Prof. PF Dequin, head of the critical care department at Tours University Hospital and member of team 1, obtained a “national PHRC” (hospital clinical research) grant (theme: Etude de l’Influence des corticostéroïdes à doses faibles sur l’évolution des pneumopathies aiguës communautaires graves / Study of the effects of low-dose corticosteroid therapy on the evolution of severe community-acquired acute lung diseases).

A. Guillon was awarded a highly competitive “Inserm research fellowship” (“contrat d’interface”) funding for 2 years to complete his PhD thesis (2012-2014 period; topic: altération de la réponse immunitaire dépendante de l’interleukine-22 lors de pathologies respiratoires / alternations in interleukin-22 receptor-dependent immune response in respiratory diseases).

Y. Jouan also received this competitive “Inserm research fellowship” funding for 2 years (from November 2016) to complete a scientific thesis (topic: De la pneumonie au Syndrome de Désférence Respiratoire Aigué (SDRA) : Rôle des populations cellulaires productrices d’IL-17 et d’IL-22 / From pneumonia to Acute Respiratory Distress Syndrome (ARDS): The role of IL-17 and IL-22-producing cell populations).

Hosting of an American researcher (Prof. Reuben Ramphal, University of Florida) by the team for 18 months (May 2013 – November 2014). Prof. Ramphal participated in developing programmes focusing on the virulence of P. aeruginosa.

Arrival in July 2016 of a new researcher (Dr. Christophe Paget, CR1 Inserm, whose expertise is in lung mucosa immunity)